Prot #CMP-001-010: A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination with Intravenous Nivolumab in Subjects with Refractory Unresectable or Metastatic Melanoma

Chandra, Sunandana (PD/PI)

Medicine, Hematology Oncology Division

Project: Research project

Status	Finished
Effective start/end date	6/2/21 → 6/2/24

Funding

Novella Clinical, LLC ((OE) Prot #CMP-001-010 // (OE) Prot #CMP-001-010)
Checkmate Pharmaceuticals, Inc. ((OE) Prot #CMP-001-010 // (OE) Prot #CMP-001-010)